2020 International Bladder Cancer Network - Results from #20

Viewing 21-32 of 32 articles

IBCN 2020: Cabozantinib Plus Durvalumab in Patients with Advanced Urothelial Carcinoma After Platinum Chemotherapy: Phase 2 ARCADIA Trial

IBCN 2020: Transition of ANX10 Expression Is a Useful Diagnostic and Prognostic Marker in Upper Tract Urothelial Carcinoma

IBCN 2020: Predictive and Prognostic Performance of IHC3 Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer

IBCN 2020: Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non Muscle-Invasive Bladder Cancer

IBCN 2020: Age is Associated with Response to Immune Checkpoint Blockade in Advanced Urothelial Carcinoma

IBCN 2020: The Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumors: Data from Multi-institutional Registry

IBCN 2020: Common Deleterious Germline Variants Shape the Urothelial Cancer Genome

IBCN 2020: The Impact of Upper Tract Urothelial Carcinoma (UTUC) on Outcomes of Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG

IBCN 2020 Specific Genetic Susceptibility Patterns of the Urothelial bladder Cancer Taxonomic Subtypes

IBCN 2020: Drug Repurposing of Bladder Cancer Driven by Patients’ Proteomic Signatures

IBCN 2020: Efficacy, Safety and Tolerability of the rBCG VPM1002BC in Patients with High-Grade NMIBC Recurrence after BCG Induction with or without BCG Maintenance Therapy – SAKK 06/14

IBCN 2020: The Ariadne’s Thread of FGFR3

1
2